mdlinx mdlinx
Latest (64) Full Text Articles (1329) Article Summary

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
The Lancet - Early Online Publication,  Evidence Based Medicine  Clinical Article

In individuals with 5–year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. This benefit greatly exceeds any known hazards of statin therapy. Under present guidelines, such individuals would not typically be regarded as suitable for LDL–lowering statin therapy. The present report suggests, therefore, that these guidelines might need to be reconsidered.

Methods
  • This meta–analysis included individual participant data from 22 trials of statin versus control (n=134537; mean LDL cholesterol difference 1.08 mmol/L; median follow–up 4.8 years) and five trials of more versus less statin (n=39612; difference 0.51 mmol/L; 5.1 years).
  • Major vascular events were major coronary events (ie, non–fatal myocardial infarction or coronary death), strokes, or coronary revascularisations.
  • Participants were separated into five categories of baseline 5–year major vascular event risk on control therapy (no statin or low–intensity statin) (<5%, ≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in each, the rate ratio (RR) per 1.0 mmol/L LDL cholesterol reduction was estimated.

Results
  • Reduction of LDL cholesterol with a statin reduced the risk of major vascular events (RR 0.79, 95% CI 0.77–0.81, per 1.0 mmol/L reduction), largely irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all–cause mortality.
  • The proportional reduction in major vascular events was at least as big in the two lowest risk categories as in the higher risk categories (RR per 1.0 mmol/L reduction from lowest to highest risk: 0.62 [99% CI 0.47–0.81], 0.69 [99% CI 0.60–0.79], 0.79 [99% CI 0.74–0.85], 0.81 [99% CI 0.77–0.86], and 0.79 [99% CI 0.74–0.84]; trend p=0.04), which reflected significant reductions in these two lowest risk categories in major coronary events (RR 0.57, 99% CI 0.36–0.89, p=0.0012, and 0.61, 99% CI 0.50–0.74, p<0.0001) and in coronary revascularisations (RR 0.52, 99% CI 0.35–0.75, and 0.63, 99% CI 0.51–0.79; both p<0.0001).
  • For stroke, the reduction in risk in participants with 5–year risk of major vascular events lower than 10% (RR per 1.0 mmol/L LDL cholesterol reduction 0.76, 99% CI 0.61–0.95, p=0.0012) was also similar to that seen in higher risk categories (trend p=0.3).
  • In participants without a history of vascular disease, statins reduced the risks of vascular (RR per 1.0 mmol/L LDL cholesterol reduction 0.85, 95% CI 0.77–0.95) and all–cause mortality (RR 0.91, 95% CI 0.85–0.97), and the proportional reductions were similar by baseline risk.
  • There was no evidence that reduction of LDL cholesterol with a statin increased cancer incidence (RR per 1.0 mmol/L LDL cholesterol reduction 1.00, 95% CI 0.96–1.04), cancer mortality (RR 0.99, 95% CI 0.93–1.06), or other non–vascular mortality.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

Last month's top read Top Articles of 2013

1 Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy Clinical Infectious Diseases, January 30, 2014    Clinical Article

2 Prescribing of high-dose acetaminophen products discouraged Full Text U.S. Pharmacist, March 11, 2014    Free full text    Clinical Article

3 Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents Expert Opinion on Pharmacotherapy, March 17, 2014    Review Article

4 New antiviral agents for the treatment of hepatitis C: ABT-450 Expert Opinion on Pharmacotherapy, March 19, 2014    Review Article
Exclusive Author Commentary

5 Use of proton pump inhibitors for the provision of stress ulcer prophylaxis: Clinical and economic consequences PharmacoEconomics, February 11, 2014    Clinical Article

6 Collaborative practice model between cardiologists and clinical pharmacists for management of patients with cardiovascular disease in an outpatient clinic Annals of Pharmacotherapy, March 5, 2014    Review Article

7 A waste walk through clinical pharmacy: How do the seven wastes of Lean techniques apply to the practice of clinical pharmacists International Journal of Pharmacy Practice, March 27, 2014    Clinical Article

8 Effect of chronic statin treatment on vascular remodeling determined by intravascular ultrasound in patients with acute myocardial infarction The American Journal of Cardiology, March 7, 2014    Clinical Article

9 Agomelatine: A new option for treatment of depression? Expert Opinion on Pharmacotherapy, February 13, 2014    Clinical Article

10 Bedtime aspirin may be more beneficial for heart patients Full Text Pharmacy Times, December 2, 2013    Free full text    Clinical Article

11 The cardiotoxicity of cancer-related drug therapies Full Text U.S. Pharmacist, March 10, 2014    Free full text    Clinical Article

12 How long does a flu shot last? The New York Times, January 20, 2014

13 Care transitions in elderly heart failure patients: Current practices and the pharmacists role The Consultant Pharmacist, March 6, 2014    Review Article

14 The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint Nutrition, Metabolism & Cardiovascular Diseases, March 7, 2014    Clinical Article

15 Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria Journal of Clinical Pharmacy and Therapeutics, March 6, 2014    Clinical Article

16 Pediatric hypertension Full Text U.S. Pharmacist, March 10, 2014    Free full text    Clinical Article

17 Impact of statin adherence on cardiovascular disease and mortality outcomes: A systematic review British Journal of Clinical Pharmacology, February 13, 2014    Evidence Based Medicine    Review Article

18 Antidepressant use and risk of coronary heart disease: Meta-analysis of observational studies British Journal of Clinical Pharmacology, March 21, 2014    Evidence Based Medicine

19 National trends in prescription drug expenditures and projections for 2014 American Journal of Health-System Pharmacy, March 4, 2014    Clinical Article

20 New cholesterol guideline: LDL goals take backseat to statins Full Text American Pharmacists Association News, November 15, 2013    Free full text    Clinical Guideline

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Other Topics in Pharmacy

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close